TABLE VII.
Cell-Based Treatment*
| Study | No. of Hips | Stage of Disease | Type of Cell-Based Therapy | Comparison Group | Mean Follow-up (Range) (yr) | Hip Survivorship (%) |
| Level-III evidence | ||||||
| Hauzeur et al.114 (2018) | 38 | Precollapse and postcollapse | BMAC | CD alone | 2 | 34.8 for CD+BMAC, and 34.8 for CD alone |
| Hernigou et al.120 (2018) | 125 | Precollapse | BMC | CD alone | 25 (20-30) | 76 for CD+BM-MSC, and 24 for CD alone† |
| Houdek et al.123 (2018) | 35 | Precollapse | BMC+PRP | None | 3 (2-4) | 84 |
| Kang et al.115 (2018) | 106 | Precollapse and postcollapse | BMC | CD alone | 4.28 | 71.7 for CD+BM-MSC, and 51 for CD alone† |
| Cruz-Pardos et al.197 (2016) | 60 | Precollapse | BMAC | CD alone | 3 (2-6.6) for CD+BMAC, and 5.3 (2-14.3) for CD alone | 46 for CD+BMAC, and 47.4 for CD alone |
| Pepke et al.198 (2016) | 24 | Precollapse | BMC | CD alone | 2 (NR) | 64 for CD+BM-MSC, and 57 for CD alone‡ |
| Tabatabaee et al.199 (2015) | 28 | Precollapse and postcollapse | BMC | CD alone | 2 (NR) | 100 for CD+BM-MSC, and 78.6 for CD alone |
| Level-IV evidence | ||||||
| Talathi and Kamath125 (2018) | 43 | Precollapse | BMAC | None | 1.3 (NR) | 94 |
| Tomaru et al.200 (2017) | 31 | Precollapse | BMAC | None | 5.8 (2-6.9) | 90.3 |
| Chen et al.201 (2016) | 9 | Precollapse | hUC-MSC | None | 24 | NR |
| Kuroda et al.202 (2016) | 10 | Precollapse | rhFGF-2 | None | 1 (NR) | 90 |
| Persiani et al.203 (2015) | 31 | Precollapse and postcollapse | BMC | None | 3.1 (2-4) | 80 |
*
BMAC = bone marrow aspirate concentrate, CD = core decompression, BM-MSC = bone marrow mesenchymal stem cells, BMC = bone marrow cells, PRP = platelet-rich plasma, NR = not reported, hUC-MSC = human umbilical cord-derived mesenchymal stem cells, and rhFGF-2 = recombinant human fibroblast growth factor-2.
†
A significant difference was found between groups.
‡
Based on radiographic evidence of disease progression.